The FDA study leading to approval of the Pulsed Light (IPL) treatment with the OptiLight technology (Lumenis) confirmed the good results seen over many years in patients with dry eye, often not responding to other treatments.
“I started this journey in 2001, when I was treating patients for rosacea and those patients were getting improvement in their dry eye,” Rolando Toyos, MD, said at the OSN Italy meeting.
IPL uses a xenon flash lamp to produce light in the 500 nm to 1000 nm wavelength range, pulsed and filtered to allow specific wavelengths of energy to be released. It treats